RNA vaccine shows promise in advanced melanoma trial
NCT ID NCT02410733
First seen Apr 06, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-stage study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check safety and find the right dose, while also looking for signs that the vaccine could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johann Wolfgang Goethe Universität Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie
Frankfurt, 60590, Germany
-
Universität Heidelberg, Dermatologie und NCT
Heidelberg, 69120, Germany
-
Universitätsmedizin Mainz, Hautklinik und Poliklinik
Mainz, 55131, Germany
-
Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.